Home Products Antibodies Primary antibodies Secondary antibodies Tag antibodies Loading control antibodies Premium polyclonal antibodies Recombinant rabbit mAbs Mouse mAbs Phosphorylated antibodies Methylation antibodies Acetylated antibodies Biochemicals Research Areas
Service & Support Custom Services Support Promotion About Us
Sign In Sign Up

IGHD Rabbit mAb  (Cat.#:AYM29817)

A
小A Scan to ask
Host: RabbitClonality: MonoclonalReactivity: HumanWBIHC
Cat.# AYM29817
Target / gene IGHD
Host Rabbit
Clonality Monoclonal
Reactivity Human
Application WB, IHC

Cat.#:AYM29817

SizePrice
50ul ¥1150.00 Add to cart
100ul ¥2100.00 Add to cart
  • Information

  • Application guide

  • Related products

  • Immunogen

  • Target data

  • Resources

  • Protocols

  • FAQs

Reactivity Human
Host Rabbit
Clonality Monoclonal
Isotype IgG
Application WBIHC
Dilution WB: 1:500 - 1:2000
IHC: 1:50 - 1:200
Predicted MW 84kDa
Observed MW 84kDa
Format Liquid
Storage Store at -20℃. Avoid freeze / thaw cycles.
Buffer: PBS with 0.75% BSA,50% glycerol,pH7.3.
Conjugate Unconjugated
Positive Human plasma
Subcellular blood microparticle,external side of plasma membrane,extracellular exosome,extracellular space,immunoglobulin complex, circulating,plasma membrane
Purification Affinity purification

Applications and conditions

Where to start

These starting conditions come from the recommended dilution, validation images, and general assay practice. Titrate for your sample and detection system.

WB Conditions for WB
Recommended dilution 1:500 - 1:2000
Suggested sample / positive control Human plasma
Key conditions Use a fresh lysate, incubate at the recommended dilution, and check the predicted and observed molecular weight
Expected result Expected signal or band near 84kDa
Controls Include a positive sample, a negative sample, and a secondary or isotype control
IHC Conditions for IHC
Recommended dilution 1:50 - 1:200
Suggested sample / positive control Human plasma
Key conditions For paraffin sections, optimize retrieval buffer pH, retrieval time, and primary incubation
Expected result Expected localization: blood microparticle,external side of plasma membrane,extracellular exosome,extracellular space,immunoglobulin complex, circulating,plasma membrane
Controls Include a positive sample, a negative sample, and a secondary or isotype control

Related products

More associated products >>

Immunogen

Immunogen Recombinant fusion protein corresponding to Human IGHD.
Sequence
View sequence
APTKAPDVFPIISGCRHPKDNSPVVLACLITGYHPTSVTVTWYMGTQSQPQRTFPEIQRRDSYYMTSSQLSTPLQQWRQGEYKCVVQHTASKSKKEIFRW

Target data

Background Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens.
Gene ID 3495
Gene name IGHD
Swiss P01880
Synonym IGHD,IGHD Rabbit mAb,Ig delta chain C region,Ig delta chain C region NIG-65,Ig delta chain C region WAH
Functions Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268). IgD is the major antigen receptor isotype on the surface of most peripheral B-cells, where it is coexpressed with IgM. The membrane-bound IgD (mIgD) induces the phosphorylation of CD79A and CD79B by the Src family of protein tyrosine kinases. Soluble IgD (sIgD) concentration in serum below those of IgG, IgA, and IgM but much higher than that of IgE. IgM and IgD molecules present on B cells have identical V regions and antigen-binding sites. After the antigen binds to the B-cell receptor, the secreted form sIgD is shut off. IgD is a potent inducer of TNF, IL1B, and IL1RN. IgD also induces release of IL6, IL10, and LIF from peripheral blood mononuclear cells. Monocytes seem to be the main producers of cytokines in vitro in the presence of IgD (PubMed:8774350, PubMed:10702483, PubMed:11282392).
Research area

Resources

Validation data

1 images

Validation images at the top of the page cover WB / IHC.

References

No papers are linked yet. Contact technical support for application examples.

Ask for examples
Customer reviews

No reviews yet. After use, you can submit a review and experiment images.

Send feedback
Support

Support can help confirm the application, sample, dilution, controls, and assay conditions.

Support center
Need help with the application?

Send the catalog number, application, sample type, and assay. Support can confirm dilution, controls, and COA or lot documents.

FAQs

Listed applications: WB, IHC. Use the validation images and recommended dilution as a starting point.
Send the catalog number and lot through the inquiry form. Support will help with the lot documents.
Use the recommended conditions as a starting concentration. Sample, fixation, and detection system may need a titration.

Protocols

Protocols
AYM29817